Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026

CVM vs OBIO: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

CVM Captures Overall Composite Edge (43.5 HOLD vs 42.9 HOLD), While OBIO Leads 3–2 on Growth & Valuation Pillars

CVM Overall Winner 6-Pillar Tally: CVM 2 – 3 OBIO (1 Tie) Matrix Metrics: CVM 6 – 4 OBIO

As of Nov 17, 2026, Cel-Sci Corporation (CVM) captures the overall head-to-head institutional edge over Orchestra BioMed Holdings, Inc. (OBIO) on higher Unified Composite conviction (43.5/100 HOLD vs. 42.9/100 HOLD) after splitting the core matrix 6–4 (led by Valuation Multiples, Profitability & Quality), while OBIO wins 3–2 across the 6-pillar growth and valuation breakdown. CVM trades at $1.91 (23.0x Forward P/E, 0.0% operating margin) versus OBIO at $7.02 (N/M Forward P/E, -195.4% operating margin).

  • Growth vs. Quality Trade-Off: CVM earns the overall head-to-head edge with a stronger Unified Composite Score (43.5/100 HOLD vs. OBIO 42.9/100 HOLD) and 0.45β · 139% Vol risk profile, whereas OBIO leads top-line expansion (-89.4% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: CVM is currently in a Breakdown options structure phase (RSI 61.8); meanwhile OBIO trades in a Markup technical trend (BREAKOUT options phase, RSI 68.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About CVM vs OBIO
CVM NYSE American Head-to-Head Winner
Cel-Sci Corporation
Biological Products, (No Disgnostic Substances)
$1.91
+14.76% 1D
Market Cap $22.5M
TTM Revenue $28,558
Forward P/E 23.0x
Beta / 30D Vol 0.45β · 139% Vol
Unified Composite Score
43.5 / 100 HOLD
Tech 23.0 Fund 47.0 Flow 50.0 Mom 54.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 62
RSI-14: 61.8 · SMA20: $1.48 · SMA50: $1.67
OBIO NASDAQ
Orchestra BioMed Holdings, Inc. Ordinary Shares
Surgical & Medical Instruments & Apparatus
$7.02
-1.4% 1D
Market Cap $570.6M
TTM Revenue $31M
Forward P/E N/M
Beta / 30D Vol 1.15β · 80% Vol
Unified Composite Score
42.9 / 100 HOLD
Tech 15.0 Fund 40.0 Flow 62.0 Mom 44.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (6.8% over 20 days), RSI 68
RSI-14: 68.1 · SMA20: $5.99 · SMA50: $5.94

6-Pillar Scorecard Institutional Category Breakdown (CVM 2 – 3 OBIO)

Columns: Metric · CVM · OBIO
1. Valuation Multiples CVM
Forward P/E 23.0x N/M
Trailing P/E 23.0x N/M
PEG Ratio 1.12x N/M
EV / Revenue N/M 18.6x
2. Growth & Scale OBIO
Revenue Growth (YoY) -62.7% -89.4%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $28,558 $31M
Market Cap $22.5M $570.6M
3. Profitability & Quality CVM
Gross Margin N/A 99.6%
Operating Margin 0.0% -195.4%
Net Profit Margin 0.0% -182.5%
Return on Equity (ROE) -252.5% -182.3%
4. Balance Sheet & Cash Flow OBIO
Cash Generation (TTM) -$17M -$64M
Cash Flow Margin N/A N/A
Net Cash / Leverage $6.6M Net Debt (1.24x D/E) $9.0M Net Debt (4.72x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning OBIO
Options Structure Phase BREAKDOWN BREAKOUT
Current IV / %ile N/A (N/A) 70.8% (<1st %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase ACCUMULATION · Neutral ACCUMULATION · Markup
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: CVM (6) vs OBIO (4)
Institutional Metric CVM OBIO Criterion Row Edge
Market Capitalization
Scale
$22.5M $570.6M Larger Scale OBIO
Trailing P/E Ratio
Valuation
23.0x N/M Lower Multiple CVM
Forward P/E Ratio
Valuation
23.0x N/M Lower Multiple CVM
Revenue Growth (YoY)
Growth
-62.7% -89.4% Higher Growth CVM
Operating Margin (TTM)
Profitability
0.0% -195.4% Higher Margin CVM
Net Profit Margin
Profitability
0.0% -182.5% Higher Margin CVM
Return on Equity (ROE)
Capital Efficiency
-252.5% -182.3% Higher ROE OBIO
52-Week Range Position
Momentum
15% ($1–$8) 89% ($3–$7) Stronger Trend OBIO
Beta / 30D Volatility
Risk Regime
0.45β · 139% Vol 1.15β · 80% Vol Lower Realized Risk OBIO
Unified Institutional Score
Composite Signal
43.5 / 100 (HOLD) 42.9 / 100 (HOLD) Higher Composite CVM
Trailing 12M Revenue (USD)
Operating Scale
$28,558 $31M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 99.6% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
1.12x PEG · N/M EV/Rev N/M PEG · 18.6x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$17M ($6.6M Net Debt (1.24x D/E)) -$64M ($9.0M Net Debt (4.72x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon OBIO +8.8 pp
CVM: +15.45% · OBIO: +24.25%
3M Horizon OBIO +10.33 pp
CVM: +16.16% · OBIO: +26.49%
6M Horizon OBIO +55.69 pp
CVM: +19.81% · OBIO: +75.5%
1Y Horizon OBIO +149.39 pp
CVM: -71.22% · OBIO: +78.17%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period CVM Revenue OBIO Revenue CVM Op. Margin OBIO Op. Margin Margin Leader
FY2011 $0M N/A -1881.0% N/A CVM
FY2012 $0M N/A -6772.3% N/A CVM
FY2013 $0M N/A -12450.1% N/A CVM
FY2014 $0M N/A -9721.4% N/A CVM
FY2022 N/A $0M N/A -924.3% OBIO
FY2023 N/A $0M N/A -1866.2% OBIO
FY2024 N/A $0M N/A -2437.5% OBIO
FY2025 N/A $30M N/A -154.7% OBIO

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
CVM BREAKDOWN
29d in phase · OBV ACCUMULATION
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow ACCUMULATION
Exact CVM Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
OBIO BREAKOUT
33d in phase · OBV ACCUMULATION
Current IV 70.8%
IV Percentile <1st %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact OBIO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
CVM Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $22.5M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
OBIO Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $570.6M market capitalization and -195.4% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ CVM vs OBIO Key Questions & Quantitative Answers

As of Nov 17, 2026, Cel-Sci Corporation (CVM) captures the overall head-to-head institutional edge over Orchestra BioMed Holdings, Inc. (OBIO) on higher Unified Composite conviction (43.5/100 HOLD vs. 42.9/100 HOLD) after splitting the core matrix 6–4 (led by Valuation Multiples, Profitability & Quality), while OBIO wins 3–2 across the 6-pillar growth and valuation breakdown. CVM trades at $1.91 (23.0x Forward P/E, 0.0% operating margin) versus OBIO at $7.02 (N/M Forward P/E, -195.4% operating margin). Growth vs. Quality Trade-Off: CVM earns the overall head-to-head edge with a stronger Unified Composite Score (43.5/100 HOLD vs. OBIO 42.9/100 HOLD) and 0.45β · 139% Vol risk profile, whereas OBIO leads top-line expansion (-89.4% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: CVM is currently in a Breakdown options structure phase (RSI 61.8); meanwhile OBIO trades in a Markup technical trend (BREAKOUT options phase, RSI 68.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

OBIO leads the Growth & Scale pillar: CVM posts -62.7% YoY revenue growth and +0.0% YoY earnings growth on $28,558 TTM revenue (N/A gross margin, 0.0% operating margin), compared with OBIO at -89.4% YoY revenue growth and +0.0% YoY earnings growth on $31M TTM revenue (99.6% gross margin, -195.4% operating margin). Across the 8-period historical trajectory (FY2011 to FY2025), CVM cumulative revenue shifted N/A while OBIO shifted N/A. In operating R&D and SG&A reinvestment, CVM deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for OBIO.

CVM screens cheaper on headline valuation multiples. CVM trades at 23.0x Forward P/E, 23.0x Trailing P/E, 1.12x PEG, and N/M EV/Revenue (unreported FCF margin), whereas OBIO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 18.6x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CVM (-252.5% ROE) versus OBIO (-182.3% ROE) capital efficiency.

In options market volatility and institutional positioning, CVM carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (0.45β · 139% Vol realized risk). By comparison, OBIO carries 70.8% implied volatility (<1st %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKOUT options structure phase (1.15β · 80% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.